TaiwanJ Pharmaceuticals Highlights Presentation at the AASLD's 2016 Liver Meeting

TaiwanJ Pharmaceuticals Co., Ltd., a pharmaceutical company focused on discovery to clinical-stage development of novel treatments for liver and inflammatory diseases, announced that it would be presenting at the 2016 American Association for the Study of Liver Disease (AASLD) Liver Meeting on Nov 14 (Mon). The poster presentation reported JKB-122’s hepatoprotective activity in a preclinical model of autoimmune hepatitis (AIH). JKB-122 alone or in combination with prednisolone showed remarkable effects in reducing liver lesions, and significantly decreased serum ALT and pro-inflammatory biomarkers in vivo. The abstract can be found at http://liverlearning.aasld.org/aasld/2016/thelivermeeting/144552. TaiwanJ is actively enrolling patients in a Phase II trial to evaluate JKB-122 in patients with AIH (NCT02556372).